ROBERT SIEGEL, HOST:
As a physician and medical researcher for nearly 50 years, Dr. Harry Selker has been a passionate advocate of translational medicine. That means he's dedicated to ensuring that innovations - his own and those of others - achieve their promise of saving and improving lives. It involves not just breaking through scientific barriers, but economic and political ones, too.
This month, we've been introducing you to bound-breakers - people who break through barriers to change the world around them. Dr. Selker is the dean of the Clinical and Translational Science Institutes and the executive director of the Institute for Clinical Research at Tufts. And that's where NPR's Arun Rath followed him around.
ARUN RATH, BYLINE: When Harry Selker was working as a cardiologist in the 1970s, thrombolytic drugs, also known as clot busters, were showing great promise against heart attacks, but their lifesaving properties were very time-sensitive.
HARRY SELKER: So for example, if you give it within the first hour, it has a 47-percent reduction of mortality. If you wait another hour - for the second hour - it has a 28-percent reduction. Another hour - 23 percent. And people were taking about 90 minutes to make the decision. So they were losing the opportunity to save patients' lives.
RATH: Selker envisioned a predictive tool, a kind of calculator that would help make the decision sooner. He knew the data to create such a tool were already out there from the clot buster research.
SELKER: We made mathematical models that kind of represented that comparison from those data. And that helped us make these predictive instruments. We built them into electrocardiographs, and it helped make better decisions.
RATH: It led to earlier treatment. Building on this success, Selker and colleagues have gone on to develop other predictive tools in areas from knee replacement therapy to opioid addiction treatment. Selker grew up in a household where he was encouraged to tinker.
In his office, he proudly shows off the first automobile shock absorber, invented by his grandfather. And while Selker's own list of patents will attest to his passion for innovation, he's equally passionate about working to ensure those innovations will have an impact.
One medical treatment Selker is pursuing right now has never delivered on its early promise for saving lives. It's a cocktail of glucose, insulin and potassium, or GIK. In studies with baboons and rabbits more than 50 years ago, it seemed to actually prevent heart attacks.
SELKER: So they would clamp off these coronary arteries, simulating coronary thrombosis, but keep infusing them with glucose, insulin and potassium. And they would do that for about six hours.
RATH: More than enough time to create a well-established heart attack in the animal.
SELKER: And then they would unclamp it, and there was no heart attack, and they didn't have cardiac arrest, these animals. And so it was very encouraging. It was extraordinary, really.
RATH: But here was the problem in translation. In human studies, GIK didn't seem to do much of anything to prevent heart attacks or damage. The research sat on the shelf. But when Dr. Selker learned about the research from a colleague and they started to discuss it, he became convinced there were fatal flaws in the human studies, including administering the GIK too late to have an effect. Selker and his colleagues designed a new test to study GIK in humans. The results were stunning.
SELKER: It reduced the composite of cardiac arrest or mortality by 50 percent in all comers. It also reduced the size of the heart attack by 80 percent.
RATH: Selker says that if additional research supports these findings, many lives could be saved with a simple therapy that costs about a hundred bucks. But he soon discovered that knowing what needed to be done wasn't enough.
SELKER: Gee, I thought, pretty much my work was done. And people would call me up and say, you know, where would we get this GIK stuff?
RATH: But there was nobody making it.
SELKER: So I started talking to the pharmaceutical companies, saying, you know, would you make this stuff? And they basically weren't interested.
RATH: GIK is a cocktail of existing off-the-shelf ingredients. A company could invest in the additional research and work to get it out to patients, but there'd be no big payoff.
SELKER: And that turns out to be one of the features that these companies are interested in. And, you know, so we have to figure out how to do that, you know? And I'm not - I won't be deterred.
RATH: Selker is now in dialogue with the FDA about the details of a definitive clinical trial that would confirm the effectiveness of GIK in acute coronary emergencies. And like so many times before, he's continuing to reach across professional boundaries.
SELKER: If you're going to try to improve things, you have to work on all angles. You have to work on all disciplines. You can't just work in biology. That would never get you anywhere. Probably the happiest moments I have in my research are - well, actually, you were at that one meeting, where there was a statistician and a cardiologist and myself.
And we often work in this very room when we're thinking up new ideas. And people in the room have ideas that I could have never thought of, but they wouldn't have bothered thinking about if I hadn't have kind of pushed them at it. The statistician has made mathematical models that are exquisite. She didn't know really much about the clinical area, but I could help her with that.
And we got databases, and we did all that stuff. So working across disciplines and personalities and different perspectives, that's - that's the good stuff for me. That really - that makes a great day.
RATH: Dr. Selker is hopeful the next clinical trial for GIK will take place by early next year. Arun Rath, NPR News, Boston.
[POST-BROADCAST CORRECTION: The audio of this story incorrectly states the time Harry Selker has been a physician as "nearly 50 years." He started practicing in 1979.]
NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.